The Importance of Voting Rights in Nanobiotix
Voting rights hold significant importance in a company’s governance structure, and this is no different for Nanobiotix. As a clinical biotechnology company, understanding how voting rights interact with shares capital might provide valuable insights for stakeholders and investors alike. In this article, we will delve into the latest data regarding Nanobiotix's voting rights and shares, enhancing our understanding of their corporate operations.
Current Share Capital Structure
Nanobiotix has reported the total number of shares outstanding as part of its capital structure. As of the last report, there are 47,426,851 shares outstanding. It’s essential for shareholders to be aware of this information, as it directly influences their voting power and overall investment strategy. Additionally, the company reported a theoretical total voting rights figure of 49,200,752 and 49,178,634 exercisable voting rights.
What Does This Mean for Investors?
For investors, these figures are crucial as they determine how many votes each shareholder can cast during important corporate decisions. This voting power can directly impact the company’s direction, making it imperative for shareholders to stay informed about any changes in share structure.
Upcoming Reporting Requirements
In compliance with French regulations, particularly Article L.233-8 II of the French Commercial Code, Nanobiotix will publish updated numbers concerning their voting rights and shares if any figures shift from what has previously been disclosed. Such transparency is vital, ensuring that investors have access to timely information about their investments.
About Nanobiotix
Nanobiotix is a leading force in the biotechnology industry, dedicated to creating groundbreaking therapeutic approaches. Established in 2003 and headquartered in Paris, France, the company focuses on innovating treatment options that significantly improve patient outcomes. With a commitment to challenging the status quo in treatment methodologies, Nanobiotix is paving the way for advancements in the sector.
Global Presence and Technological Assets
Since going public on Euronext Paris in 2012 and Nasdaq in December 2020, Nanobiotix has established a global footprint, including subsidiaries in locations such as Cambridge, Massachusetts. The company has developed over 25 patent families that support three primary nanotechnology platforms, with applications in oncology, improving bioavailability, and treating disorders of the central nervous system.
Connecting with Nanobiotix
Interested parties are encouraged to learn more about Nanobiotix by visiting their official website or following them on social media platforms like LinkedIn and Twitter to stay updated on their latest advancements and announcements. You can reach their Communications Department at +1 (617) 852-4835 or via email at contact@nanobiotix.com for more personalized inquiries.
Frequently Asked Questions
What are the voting rights associated with Nanobiotix shares?
Nanobiotix shares come with a total of 49,200,752 theoretical voting rights, allowing shareholders to participate actively in corporate governance.
Why is knowing the shares outstanding important?
The number of outstanding shares influences the voting power of shareholders. Understanding this helps in strategizing investment decisions effectively.
How often does Nanobiotix report changes in voting rights?
Nanobiotix updates its voting rights and shares capital when there are significant changes, in accordance with regulatory requirements.
Where can I find more information about Nanobiotix?
More information can be found on their official website, as well as their social media pages, where they post updates and news.
Who can I contact for media inquiries regarding Nanobiotix?
For media inquiries, you can contact their Communications Department at +1 (617) 852-4835 or reach out via email.
